Scarica l'app Stockscreener
23.80
3.16%
0.73
Pre-mercato:
23.69
-0.11
-0.46%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CPRX Giù?
Forum
Previsione
Catalyst Pharmaceuticals Inc Borsa (CPRX) Ultime notizie
NVO Eyes Global Expansion of Diabetes Drug After Strong Phase II Data - TradingView
Aug Technicals: Can Catalyst Pharmaceuticals Inc stock outperform in a bear market2026 Price Targets & Fast Exit/Entry Strategy Plans - baoquankhu1.vn
Retail Trends: Does Catalyst Pharmaceuticals Inc align with a passive investing strategy2026 Market WrapUp & Low Drawdown Momentum Ideas - baoquankhu1.vn
Catalyst Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
FDA Grants Priority Tag to Ionis' NDA for Alexander Disease Drug - TradingView
INSM Stock Gains After Arikayce Hits Goal in Label Expansion Study - TradingView
Catalyst Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
GSK's Risvutatug Rezetecan Gets Japan Orphan Drug Tag for Lung Cancer - TradingView
CPRX Technical Analysis | Trend, Signals & Chart Patterns | CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) - ChartMill
Will Catalyst Pharmaceuticals Inc benefit from government policyWeekly Loss Report & AI Forecast Swing Trade Picks - baoquankhu1.vn
Is Catalyst Pharmaceuticals Inc a momentum stock2026 Growth vs Value & Daily Chart Pattern Signal Reports - baoquankhu1.vn
Assessing Catalyst Pharmaceuticals (CPRX) Valuation After Recent Share Price Momentum Cooldown - Sahm
Why Catalyst Pharmaceutical (CPRX) is a top value stock for the long term - MSN
CPRX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Should Value Investors Buy Catalyst Pharmaceuticals (CPRX) Stock? - Yahoo Finance
Is Catalyst Pharmaceuticals Inc likely to announce a buyback2026 Risk Factors & Daily Volume Surge Signals - baoquankhu1.vn
Market Wrap: Is Catalyst Pharmaceuticals Inc likely to announce a buyback2026 Weekly Recap & Weekly Watchlist of Top Performers - baoquankhu1.vn
Catalyst Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Patent trial on Catalyst (NASDAQ: CPRX) FIRDAPSE® patents delayed to May 18, 2026 - Stock Titan
Catalyst Pharmaceuticals, Inc. Files Form 8-K with SEC Detailing Company Information and Stock Listing on NASDAQ - Minichart
Catalyst Pharma Patent Trial Against Hetero USA Delayed - TipRanks
Catalyst Pharmaceuticals IncDistrict court delays bench trial to May 18, 2026SEC filing - marketscreener.com
Catalyst Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Catalyst Pharmaceuticals (NASDAQ: CPRX) FIRDAPSE patent trial pushed to May 2026 - Stock Titan
Catalyst Pharmaceuticals (CPRX) reports record Q4 and full year 2025 results - MSN
Catalyst Pharmaceuticals, Inc. (CPRX): A bull case theory - MSN
Agios Pharmaceuticals Stock Declines 23% in 6 Months: Here's Why - TradingView
Analyst Upgrade: Is Catalyst Pharmaceuticals Inc a defensive stock2026 Macro Moves & Scalable Portfolio Growth Methods - baoquankhu1.vn
CPRX Stock Price, Quote & Chart | CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) - ChartMill
(CPRX) Risk Channels and Responsive Allocation - Stock Traders Daily
Aug Rallies: Should I trade or invest in Catalyst Pharmaceuticals IncOptions Play & Community Verified Trade Signals - baoquankhu1.vn
Merger Talk: Does Catalyst Pharmaceuticals Inc align with a passive investing strategy2026 Macro Moves & Weekly Setup with High ROI Potential - baoquankhu1.vn
A Look At Catalyst Pharmaceuticals (CPRX) Valuation After Recent Share Price Softness - Yahoo Finance
Is Catalyst Pharmaceuticals (CPRX) Pricing Reflect Long Term Value After Rare Disease Interest? - Yahoo Finance
Here's why Catalyst Pharmaceutical (CPRX) is a strong value stock - MSN
Is Catalyst Pharmaceuticals (CPRX) Offering Value After Strong Multi‑Year Share Price Gains - simplywall.st
Assessing Catalyst Pharmaceuticals (CPRX) Valuation After Recent Share Price Weakness - Sahm
Catalyst Pharmaceuticals Touts Firdapse Growth, Agamree Traction as Fycompa Faces Generics - MarketBeat
Fundsmith LLP Acquires 654,721 Shares of Catalyst Pharmaceuticals, Inc. $CPRX - MarketBeat
United Therapeutics Stock Surges 32% in 6 Months: Here's Why - TradingView
Kennedy Capital Management LLC Grows Position in Catalyst Pharmaceuticals, Inc. $CPRX - MarketBeat
EPS Watch: Is Catalyst Pharmaceuticals Inc a defensive stockAnalyst Downgrade & Entry Point Confirmation Alerts - baoquankhu1.vn
2025 results exceed expectations as 2026 outlook set, Catalyst Pharmaceuticals projects - Traders Union
Beam Therapeutics Stock Surges 23% in 6 Months: What's Driving It? - TradingView
Catalyst Pharmaceuticals, Inc. $CPRX Shares Sold by Fieldview Capital Management LLC - MarketBeat
Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) Presents a Compelling Value Investment Case - ChartMill
Catalyst Pharmaceuticals: Exceptional Fundamentals Trading at 20-33% Discount - Investing.com
Zacks.com featured highlights include Air Lease, National Energy, Catalyst and JBT Marel - The Globe and Mail
Catalyst Pharmaceuticals at Barclays Conference: Strategic Growth and Challenges By Investing.com - Investing.com Canada
Geopolitical Volatility Boosts Value Investing: 4 Low-PEG Picks - TradingView
Catalyst Pharmaceuticals: Exceptional Fundamentals Trading at 20-33% Discount - TradingView
BMY Advances CELMoD Program With Positive Phase III Results - TradingView
Neo Ivy Capital Management Sells 104,411 Shares of Catalyst Pharmaceuticals, Inc. $CPRX - MarketBeat
Intech Investment Management LLC Sells 46,656 Shares of Catalyst Pharmaceuticals, Inc. $CPRX - MarketBeat
Why Catalyst Pharmaceuticals (CPRX) Is Up 5.0% After Raising Its 2026 Revenue Outlook And What’s Next - Sahm
Operating margin % of Catalyst Pharmaceuticals, Inc. – HAM:CN2 - TradingView
(CPRX) Movement as an Input in Quant Signal Sets - Stock Traders Daily
How Much Upside is Left in Catalyst (CPRX)? Wall Street Analysts Think 43.34% - Finviz
Catalyst Pharmaceuticals to Showcase Real‑World Findings in Duchenne Muscular Dystrophy and Host Vamorolone-Focused Symposium at the 2026 MDA Clinical & Scientific Conference - The Manila Times
Catalyst Pharmaceuticals to Present Real-World Findings on Duchenne Muscular Dystrophy at 2026 MDA Conference - Quiver Quantitative
1.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):